Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Many important properties and potential health benefits of nicotinamide riboside have been identified since discovery of its role in the human NAD metabolic cycle over a decade ago.
Robotic-arm assisted surgery using the Stryker Mako System may yield better functional results for total hip, as well as for partial or total knee replacement patients due to…
Current therapeutic options for non-small cell lung cancer (NSCLC) are ever-evolving with the possibility of solely immunotherapy-based treatment regimens on the near horizon for certain patients.
Nicotinamide riboside appears to be the best precursor supplement available to help maintain or increase NAD+ levels. All cells and tissues can use it, and at high doses…
